Lisata Therapeutics, Inc. (NASDAQ:LSTA) Stock Short Interest Report for September

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 39,407 shares, a decline of 76.1% from the September 15th total of 164,953 shares. Based on an average daily trading volume, of 362,256 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.5% of the company’s stock are sold short.

Lisata Therapeutics Trading Down 11.7%

LSTA opened at $1.06 on Friday. The stock’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $2.76. The stock has a market cap of $9.55 million, a PE ratio of -0.65 and a beta of 0.94. Lisata Therapeutics has a 1-year low of $0.99 and a 1-year high of $5.07.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Thursday, August 6th. The company reported ($0.32) EPS for the quarter. Equities analysts forecast that Lisata Therapeutics will post -1.09 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Lisata Therapeutics in the second quarter valued at about $1,730,000. Bank of America Corp DE bought a new position in Lisata Therapeutics in the second quarter valued at about $35,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Lisata Therapeutics in the second quarter valued at about $157,000. GSA Capital Partners LLP bought a new position in Lisata Therapeutics in the second quarter valued at about $321,000. Finally, Rangeley Capital LLC acquired a new position in Lisata Therapeutics during the first quarter worth about $376,000. 8.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies intended to improve the treatment of solid tumors. The company’s approach centers on tumor-penetrating peptides designed to selectively target the tumor microenvironment and help therapeutic agents reach cancer cells more effectively.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is designed to activate the CendR pathway, which may increase the penetration and distribution of co-administered anticancer treatments within tumors.